A Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases (NCT06932458)
A Phase II Single-arm Clinical Trial of Primary Retroperitoneal Lymph Node Dissection in Patients With Testicular Seminoma With Limited Retroperitoneal Metastases
🩺 Plain-English Summary (8th-Grade Level)
Testicular cancer represents 1% of adult neoplasms and is the most common solid malignancy in young men. At diagnosis, approximately 90% of cases are germ cell tumours (GCT), categorised as either seminoma (55-60%) or non-seminoma types (40-45%). For many years, the management of patients with CS IIA/B seminoma and retroperitoneal lymph node involvement ≤ 3 cm are eligible for treatment with either radiotherapy or chemotherapy Despite high cure rates for CS II seminoma (approximately 90%) with chemotherapy or radiotherapy, concerns persist regarding short and long-term treatment-related toxicities (such as increased risks of cardiovascular disease and secondary malignancies As such, an alternative strategy which has been explored in this study is the role of RPLND for the management of these patients
Who can join: Review the eligibility criteria below.
Location: London Health Sciences Centre — London, Ontario
Age range: 18 Years
🧪 Interventions in This Study
- Retroperitoneal Lymph Node Dissection (PROCEDURE)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- London Health Sciences Centre — London, Ontario
📞 Contact the Study Coordinator
Phone: (519) 685-8500
Email: Kaydee.Connors@lhsc.on.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Testicular Cancer
- WATChmAN Virtual Testicular Cancer Clinic — Toronto, Ontario
- Pursuing Exploration Into the Supportive Care Needs and Intervention Preferences of Survivors of Testicular Cancer — Indianapolis, Indiana
- Low-Dose CT - Stage I Testicular Cancer — Toronto, Ontario
- Virtual Testis Cancer Lay Support and Survivorship Aim 2 — Chapel Hill, North Carolina
- Patient Reported Experiences With Sparing External Oblique Fascia Vs Standard Inguinal Orchiectomy — Loma Linda, California
- Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection. — Indianapolis, Indiana
Explore by condition: All Testicular Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.